Today: 21 July 2026
Aviva share price slumps 5% on Friday: what to watch for AV.L before results
24 January 2026
2 mins read

Aviva share price slumps 5% on Friday: what to watch for AV.L before results

London, Jan 24, 2026, 08:30 GMT — Market closed

Aviva’s London-listed shares ended Friday down 5.17%, closing at 619.40 pence after opening at 652.40p and slipping to the low of the session. Trading volume climbed to 18.4 million shares. The stock remains far from its 52-week peak of 700.60p, data from London South East shows.

The selloff came as UK stocks finished the week a touch lower, investors shaken by geopolitical concerns and shifting toward safer sectors. The FTSE 100 fell 0.07% on Friday, breaking a three-week run of gains, Reuters reported.

Aviva didn’t release any new regulatory announcements on Friday, according to the London South East RNS feed. That leaves investors to interpret Wednesday’s price action mainly through positioning and the overall market risk sentiment ahead of Monday’s open. The most recent RNS headline remains a director/PDMR shareholding notice from Jan. 16.

Aviva rolled out updates this week to its health services linked to individual protection policies. The insurer’s DigiCare+ app now provides unlimited 24/7 digital GP appointments for policyholders and their families, up from the previous cap of three per year. It also increased allowances for mental health, bereavement, and nutrition support, while introducing a personal training option. Fran Bruce, managing director of protection at Aviva, described the upgrades as delivering “accessible, round-the-clock healthcare and wellbeing services.” Aviva

Aviva’s asset management division has bolstered its UK wealth team with new hires. Aviva Investors named Eoin Rooney as director of digital channels and Serena Burton as strategic partners director, both transferring from Vanguard, Funds Europe reports. Smera Ashraf, head of EMEA wealth, highlighted that these recruits add “experience and expertise from within the UK retail space.” Funds Europe

Aviva Capital Partners has teamed up with Southampton City Council and the University of Southampton to redevelop the 4.6-acre site of the former Toys “R” Us near Southampton Central station. The plot has been empty since 2018. The partners are weighing temporary uses initially or a potential demolition in 2026 as they move forward. Aviva

For equity investors, a bigger risk lies in the capital and integration efforts around Direct Line. On Jan. 5, Aviva announced that the Prudential Regulation Authority had approved withdrawing Direct Line’s Solvency II partial internal model for two UK subsidiaries. After Dec. 31, 2025, capital requirements for those units can be calculated using the standard formula. Aviva said this shift could boost its full-year 2025 group shareholder solvency ratio by roughly 2 percentage points — a key gauge of an insurer’s capital buffer relative to Solvency II regulatory demands.

But those capital gains aren’t guaranteed. Aviva has warned that shifting Direct Line’s business onto its internal model still needs PRA approval. The group aims for over £0.5 billion in total capital synergies by around the end of 2026 — though delays are possible if regulators, markets, or underwriting results take a downturn.

As the London market rests for the weekend, all eyes will be on whether Friday’s decline sparks further selling once trading kicks back in, or if buyers step in near the 620p level. Given the lack of fresh company announcements, any broker update, sector insight, or new filing could swiftly trigger the next move.

Aviva’s 2025 full-year results will land on March 5. Investors will be keenly watching for fresh details on capital, solvency, and updates regarding the Direct Line integration.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Axiom Biosciences Eyes Hong Kong IPO to Tap Booming China Biotech Market
    July 21, 2026, 8:07 AM EDT. Axiom Biosciences, a biotechnology company based in the US, is considering pursuing an initial public offering (IPO) in Hong Kong. The company's initiative seeks to benefit from China's growing strength in clinical development and the rapid expansion of its biotech industry.
British American Tobacco share price in focus before London open after buyback disclosure
Previous Story

British American Tobacco share price in focus before London open after buyback disclosure

Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week
Next Story

Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week

Go toTop